Takeda Pharmaceutical (TAK) Common Equity: 2017-2025

Historic Common Equity for Takeda Pharmaceutical (TAK) over the last 9 years, with Mar 2025 value amounting to $45.5 billion.

  • Takeda Pharmaceutical's Common Equity fell 7.38% to $45.5 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $45.5 billion, marking a year-over-year decrease of 7.38%. This contributed to the annual value of $45.5 billion for FY2025, which is 9.73% down from last year.
  • Takeda Pharmaceutical's Common Equity amounted to $45.5 billion in FY2025, which was down 9.73% from $50.4 billion recorded in FY2024.
  • Takeda Pharmaceutical's Common Equity's 5-year high stood at $50.6 billion during FY2022, with a 5-year trough of $45.5 billion in FY2025.
  • For the 3-year period, Takeda Pharmaceutical's Common Equity averaged around $47.7 billion, with its median value being $47.0 billion (2023).
  • Per our database at Business Quant, Takeda Pharmaceutical's Common Equity increased by 12.28% in 2021 and then fell by 9.73% in 2025.
  • Yearly analysis of 5 years shows Takeda Pharmaceutical's Common Equity stood at $48.8 billion in 2021, then increased by 3.70% to $50.6 billion in 2022, then dropped by 7.12% to $47.0 billion in 2023, then climbed by 7.23% to $50.4 billion in 2024, then dropped by 9.73% to $45.5 billion in 2025.